Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Twin Peaks, Sherlock, and Lost are among the masterful mystery TV shows that keep every episode unpredictable and impossible ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of 2024. Now, the momentum has dissipated, and most companies are bracing for ...

Announcing the submission of a marketing application for its experimental weight loss drug, orforglipron, in China, Eli Lilly (LLY) said on Wednesday that it plans to invest $3B in the country over ...

Hims & Hers Health (HIMS) has made a major change in its PR function with the hiring of Kathryn Beiser, who has served Lilly (LLY) as the weight loss drugmaker’s chief communications officer for five ...

Eli Lilly commits $3 billion to China expansion spanning the next ten years Funding targets orforglipron manufacturing, the company’s oral GLP-1 therapy for weight management Marketing authorization ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more effective than competing products. That's ...

Eli Lilly (LLY) is quietly emerging as one of the most talked-about stock split candidates for 2026, and that's not just because of headlines. Analysts point to its elevated share price as a barrier ...